Related Articles
Measurement of plasminogen activator system components in plasma and tumor tissue extracts obtained from patients with breast cancer: An EORTC Receptor and Biomarker Group collaboration
PROTEASES ASSOCIATED WITH GYNECOLOGICAL TUMORS
Quantitative RT-PCR assays for the determination of urokinase-type plasminogen activator and plasminogen activator inhibitor type 1 mRNA in primary tumor tissue of breast cancer patients: Comparison to antigen quantification by ELISA
EFFECT OF TUMOR SIZE ON THE ASSOCIATION BETWEEN PS2 AND CATHEPSIN-D IN PRIMARY BREAST-CANCER
Urokinase-type plasminogen activator and plasminogen activator inhibitor type 1 and type 2 in stage I malignant melanoma